Tissue Regenix adds European bladder matrix patent

RNS Number : 2905N

Tissue Regenix Group PLC

25 July 2014

 



Tissue Regenix Group Plc

Tissue Regenix adds European bladder matrix patent to global exclusive licence portfolio

YORK, 25 July 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, has received a decision to grant a European patent covering the use of its dCELL® technology in creating tissue implants for bladder repair.

The Group has exclusive access to a range of patents protecting its core processes in major markets, and is adding to these by working with its technology partner, the University of Leeds, to protect individual products and processes.

Tissue Regenix's dCELL® decellularisation process removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold, which is not rejected by the patient's body, and which can then be used to repair diseased or worn-out body parts.

This is the latest patent covering the use of the dCELL® decellularisation process and follows a recent announcement in May 2014 that a similar patent, related to tissue matrices for bladder implantation, has been granted in the United States.

Antony Odell, CEO of Tissue Regenix commented: "The global urology device market is one of the largest growth areas for the medical devices industry, and is estimated to be worth $8.6bn by 2022,[1] driven by treatment demands for an ageing population."

"As part of the global roll-out of our dCELL® technology, this latest European bladder patent adds to our ever-growing global portfolio, and helps Tissue Regenix achieve our aim of commercialising new ways to treat an array of urological disorders."

Tissue Regenix has offices in the UK and US and is concentrated on the global commercialisation of its dCELL® technology.

ENDS

For Further Information

Tissue Regenix Group Plc:                                                           [phone]

Antony Odell

Ian Jefferson

Jefferies International Ltd:                                                         [phone]

Simon Hardy

Harry Nicholas

Newgate Communications:                                                        [phone]

Andrew Adie                                                                    

Stephanie Dobbs                                                            

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

---

[1] Urology devices: World market outlook 2012-2022, Visiongain, November 2012

 

END

 

 

NRARIMRTMBBTBAI